← Back to news
NewsBIOLOGICALS : JOURNAL OF THE INTERNATIONAL ASSOCIATION OF BIOLOGICAL STANDARDIZATIONSaturday, May 9, 2026 · May 9, 2026

Status and progress in the development of rDNA-derived Tocilizumab and its biosimilars for treatment of rheumatoid arthritis.

WHY IT MATTERS

Recent peer-reviewed research on Polyarticular juvenile idiopathic arthritis that may be relevant for patients and caregivers.

The immune system unintentionally targets the synovial lining of the joints in rheumatoid arthritis (RA), a chronic autoimmune disease that causes inflammation, discomfort, and gradual joint destruction. A humanized anti-IL-6R monoclonal antibody (mAb), tocilizumab (TCZ) is primarily used to treat r...

Read on PubMed
Read the original at Biologicals : journal of the International Association of Biological Standardization
ResearchPubMedPolyarticular juvenile idiopathic arthritisHumansBiosimilar Pharmaceuticals

Related conditions

Polyarticular juvenile idiopathic arthritis

Related news

Int J Circumpolar Health · -222 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.
Ther Adv Rare Dis · -192 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.
Health Inf Sci Syst · -192 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.
J Allergy Clin Immunol Glob · -39 days ago
Emerging trends and research hot spots in inborn error of immunity: A bibliometric perspective
Published in J Allergy Clin Immunol Glob. Alblooshi H et al.